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Clenbuterol is a well-known growth promoter, illegally used in farm animals, especially in cattle.
Samples collected for the screening of 2-agonist residues in Portuguese Azores Islands must travel
through all the nine islands until they reach Azores Central Laboratory. If any suspicious sample is
detected, it must be further transported to the National Reference Laboratory in Lisbon for confirmation.
As a consequence of these circumstances, samples are submitted to different transport and storage
times, as well as different temperature conditions and in some cases successive freezing and thawing
cycles. As clenbuterol is the most detected 2-agonist growth promoter in the Portuguese Residue
Monitoring Plan, studies were conducted on the stability of this compound in incurred samples (bovine
liver and urine) at +4, -20 and -60 °C over time. Samples kept at -20 °C were also analyzed over
time after successive freezing and thawing cycles. The analyses of clenbuterol over time were
performed by gas chromatography-mass spectrometry (GC-MS) with selected ion monitoring (SIM).
Clenbuterol in incurred urine and liver samples was significantly stable up to 20 weeks at -20 and
-60 °C and after, at least, six consecutive freezings and thawings. At +4 °C, clenbuterol remained
stable, at least until 12 weeks in urine and up to 20 weeks in liver.
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INTRODUCTION
Clenbuterol [4-amino-3,5-dichloro-R-(tert-butylaminometh-
yl)benzyl alcohol] is an orally active 2-agonist authorized for
clinical use in veterinarian medicine as bronchodilatant in
bovines, equines and pets, or as a tocolitic in cows with a
maximum residue level (MRL) of 0.5 µg kg-1 for liver/kidney
and 0.1 µg kg-1 for muscle or 0.05 µg kg-1 for milk (1-3). It
was observed in several animal species that 2-agonist com-
pounds, especially clenbuterol, could act as a repartitioning agent
and was able to decrease fat deposition with enhanced protein
accumulation when administered orally at high doses. This
growth promoting property of 2-agonists is still used in
intensive production of cattle and other farm animals around
the world (2). Within the European Union (EU) their use as
growth promoting agents is banned since 1996. The ingestion
of contaminated edible tissues containing residues of such
compounds has been responsible for several human intoxications
in some European countries (4-8) including Portugal (9, 10).
Control of the illegal use of 2-agonists as well as other
veterinary drugs and growth promoters, in intensive animal
production, is regularly performed within the EU by the
application of Residue Monitoring Programs. The overall
strategy of control includes the surveillance of live animals with
the collection of urine, feed, water and edible tissues like muscle
and liver at slaughterhouses.
Under the application of the Portuguese Residue Monitoring
Plan in Azores Islands, 2-agonist immunoassay screening tests,
by enzyme-linked immunosorbent assay (ELISA), are performed
in Azores Central Laboratory. For this task, urine and liver
samples are collected in each of the nine islands and preserved
under cold storage until transportation to the laboratory. If the
transportation is performed in 24 to 48 h after collection, samples
are maintained refrigerated at +4 °C. If not, samples are frozen
* Corresponding author: fjramos@ci.uc.pt, tel.: + 351 239859994,
fax: + 351 239827126.
† Direcc¸a˜o Regional do Desenvolvimento Agra´rio.
‡ Laborato´rio Nacional de Investigac¸a˜o Veterina´ria.
§ Faculdade de Farma´cia da Universidade de Lisboa.
| Faculdade de Farma´cia da Universidade de Coimbra.
⊥ Universidade dos Ac¸ores.
910 J. Agric. Food Chem. 2009, 57, 910–914
10.1021/jf802995e CCC: $40.75  2009 American Chemical Society
Published on Web 01/12/2009
at -20 °C until transportation is made possible. At the
laboratory, and until analysis, samples are stored under refrig-
eration (+4 °C) or frozen conditions (-20 °C), for periods of
time that can vary from one day to several weeks, depending
on the number of samples available for analysis. If any
suspicious sample is detected, analytical confirmation must be
conducted according to the criteria of Commission Decision
2002/657/EC (11). Since confirmation is performed in Lisbon
at Laborato´rio Nacional de Investigac¸a˜o Veterina´ria (LNIV),
the National Reference Laboratory, samples must be subjected,
once more, to freezing, storage and transportation until further
analysis.
From this particular situation involving Portuguese Azorean
islands and the control of 2-agonist residues in live animals
and their products emerges the question of the stability of these
compounds in urine and liver samples submitted to storage time
and temperature extreme conditions with several freezing and
thawing cycles.
In the literature, a study performed on the storage stability
of clenbuterol in incurred urine as Certified Reference Material
concludes for the stability of the compound in this biological
matrix (12). This study was performed with incurred lyophilized
samples from which conclusions cannot be extrapolated to
laboratory samples. Two other studies, using fortified urine
samples instead of incurred urine, were found: in the first it
was found that clenbuterol recovery diminished in urine during
frozen storage at -15 °C (13), but in the second one no
clenbuterol degradations occurred during storage at -20 °C or
at -60 °C (14).
For frozen incurred lyophilized liver samples with clenbuterol,
similar studies were performed for the production of Certified
Reference Material (15) and concluded in favor of the stability
of the compound. The same conclusions were found for liver
samples, when stored at -30 °C without any prehomogenization
(16). Nevertheless, in a previous study it was also found that in
prehomogenated liver clenbuterol was unstable at both -20 and
-60 °C (14).
Other studies (17, 18) demonstrated an elevated stability for
clenbuterol during several processes of cooking tissues.
The aim of this paper was to study the stability of clenbuterol
in incurred urine and liver samples under storage at +4, -20
and -60 °C during 20 weeks, and under several freezing and
thawing cycles at -20 °C, in an attempt to safeguard the
analytical results of the official control.
MATERIAL AND METHODS
Reagents and Supplies. Clenbuterol was obtained from
Sigma (St. Louis, MO), and the internal standard (IS) d6-
clenbuterol was provided by RIVM (Bilthoven, The Nether-
lands). The solid phase extraction (SPE) columns were from
United Chemical Company (Bristol, PA) for urine (Clean Screen
DAU 500) and for liver (Clean Screen DAU 1M6). The
derivatizing reagent was composed of N-methyl-N-trimethyl-
sililtrifluoroacetamide (MSTFA) from Macherey Nagel (Hoerdt,
Germany), trimethyliodosilane (TMSI) from Sigma (Madrid,
Spain) and dithioerythritol (DTI) from Merck (Darmstadt,
Germany) [MSTFA/TMSI/DTI, 1000:2:2 (mL/mL/g)]. All other
reagents were of analytical grade, and gases were supplied by
Arliquid (Lisbon, Portugal).
Animal Treatment and Attainment of Incurred Samples.
One Holstein cow (500 kg) was orally treated with clenbuterol:
7.5 µg per kg b.w. per day for two days, and 3 µg per kg b.w.
per day for eight more days, in single doses. On the second
day urine was collected, homogenized and separated in 10 mL
aliquots in current polypropylene urine tubes (lot with 96
aliquots). After slaughter on the eleventh day, the liver (9.1 kg)
was collected and separated in four strips after removal of 10 g,
in duplicate, from each one of the five liver lobes (19): lobus
hepatis dexter (hd), lobus hepatis sinister (hs), lobus quadratus
(lq), lobus caudatus (lc) and processus papillaris (pp).
Clenbuterol Homogeneity and Stability Studies. Nine
random 10 mL aliquots of incurred urine and ten samples of
10 g, two from each one of the five liver lobes, of incurred
liver were analyzed fresh for previous homogeneity tests.
Incurred urine aliquots and liver strips were stored at +4, -20
and -60 °C. Two sets of incurred urine aliquots and two sets
of incurred liver strips were stored at -20 °C. Subsequently 10
mL aliquots of incurred urine and 10 g of incurred liver were
analyzed in triplicate at several storage times from each one of
the storage conditions. One set of incurred urine and of incurred
liver samples stored at -20 °C were also analyzed after
successive freezing and thawing cycles.
Extraction Procedures. The analytical procedure used for
clenbuterol analysis is described elsewhere (20, 21). Briefly, to
urine (10 mL) or liver (10 g) samples respectively 4.0 and 20.0
mL of 0.2 M acetate buffer pH 5.2 and 50 µL of -glucoronidase
(30 U mL-1)/arylsulfatase (60 U mL-1) were added. As internal
standard, d6-clenbuterol (5 ng mL-1 in urine and 5 ng g-1 in
liver) was added. Hydrolysis took place overnight at 45-50
°C. For liver samples an additional acid precipitation with 50
mL of hydrochloric acid was performed and the pH was brought
to 6.0 ( 0.3 with 1 M potassium hydroxide. Samples were then
homogenized with 0.1 M phosphate buffer pH 6, and extracted
using SPE columns. In summary, after sample centrifugation,
the supernatant was decanted onto a CleanScreenDAU cartridge,
previously preconditioned with methanol, water and phosphate
buffer. The column was washed with acetic acid and methanol,
and elution was done with an ethyl acetate/ammonium hydroxide
solution (97:3, v/v). Eluate was evaporated to dryness, under a
current of dehydrated air, at 45 °C, and the dry residue was
kept in a desiccator, under vacuum, for at least 4 h, until
derivatization.
Derivatization. Dry eluates were derivatized with 50 µL of
MSTFA/TMSI/DTI at 65 °C for 20 min. They were left to cool
to room temperature and transferred to the GC-MS system.
GC-MS Equipment and Parameters. Gas chromatogra-
phy-mass spectrometry (GC-MS) analysis was performed on
a Hewlett-Packard HP 6890 gas chromatograph coupled to a
Hewlett-Packard HP 5973 quadrupole mass analyzer (Hewlett-
Packard, Palo Alto, CA). An HP-5MS column (30 m × 0.25
mm i.d. × 0.25 µm of film thickness, Agilent, Palo Alto, CA)
was used. The mass spectrometer was operated in the electron
impact (EI) mode and in selected ion monitoring (SIM)
acquisition. Sample injection volume was 2 µL (splitless, 1 min)
with injector temperature at 230 °C using helium as carrier gas
(1.2 mL min-1). Oven programmed temperature was as follows:
0.4 min at 100 °C, up 10 °C min-1 to 200 °C (3 min), up 10 °C
min-1 to 300 °C (5 min), with the interface temperature kept at
320 °C. Diagnostic ions used for detection and identification
of clenbuterol as trimethylsilyl derivative were m/z 86, 300, 335,
337 and 405. For quantitative determination m/z 86 and 92,
respectively, for clenbuterol and d6-clenbuterol were used.
Calibration Curves. For clenbuterol quantification a new
calibration curve was used for each daily determination. These
calibration curves were obtained with blank samples of urine
and liver, free of clenbuterol, as verified by previous GC-MS
analysis. The blank samples were spiked with clenbuterol at 4
to 6 concentration levels covering the range around the expected
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clenbuterol concentration, including one without any addition
of clenbuterol (zero calibrant). These calibrants were also spiked
with the same quantity of IS d6-clenbuterol as the samples.
RESULTS AND DISCUSSION
The results of the homogeneity study of clenbuterol concen-
tration in the urine lot and clenbuterol distribution in the liver
are shown in Figures 1 and 2, and they demonstrate that the
materials were homogeneous. The variability expressed as a
coefficient of variation (CV) of mean and observed between
individual aliquots of urine and between individual liver samples
was very low, respectively 5.28% and 6.21%, and can be
considered equivalent to the respective repeatability of the
method. According to EU legislation (11) the typical repeat-
ability should be between 18 and 24%, for concentrations of 5
ng mL-1 (similar to the clenbuterol concentration of the incurred
urine), and between 15 and 20%, for concentrations of 18 ng
g-1 (similar to the clenbuterol concentration of the incurred
liver), but the repeatability of the GC-MS method for urine
and for liver samples, at similar concentrations, were found to
range from 0.28 to 5.36%, for the urine, and from 1.29 to 9.27%,
for the liver. The prosecution of the clenbuterol stability studies
in both matrices was therefore possible. Moreover, the confir-
mation that liver has a uniform clenbuterol distribution, as stated
by Gude and co-workers (16) is important for all those leading
with sampling and analysis for official control, since it allows
the collection of any part of this organ for residue monitoring.
The precision of the analytical methodology for clenbuterol
determination in each type of sample, in intralaboratorial
reproducibility conditions, had been estimated from daily
calibrations curves in terms of the coefficient of variation of
the method (CVm). The knowledge of the CVm for clenbuterol
determination in urine (7.49%, n ) 59, in the range 0 to 10
ng/mL) and liver (9.20%, n ) 45, in the range 0 to 24 ng/g) is
of extreme value for conclusions about clenbuterol stability.
The results from the clenbuterol stability studies in incurred
urine and liver are shown in Figures 3 and 4. The average
clenbuterol concentration and standard deviation in terms of CV
of mean for all the results obtained in each study are shown in
Tables 1 and 2. Those results for urine and for liver, at each
storage condition, show a small CV, each one closer of the
respective CVm, except for liver under successive freezings and
thawings. Here a higher CV (15.10%) was verified which could
be explained by the elevated concentration obtained at 12 weeks
of storage (coincident with the fourth thawing). This superior
concentration could be explained by some kind of metabolic
activity which was responsible eventually for increasing bio-
availability of clenbuterol, from some clenbuterol conjugated
forms which were not initially detectable due to aromatic and
Figure 1. Homogeneity of clenbuterol concentration in the lot of incurred
urine aliquots.
Figure 2. Homogeneity of clenbuterol distribution in five liver lobes: lobus
hepatis dexter (hd), lobus hepatis sinister (hs), lobus quadratus (lq),
processus caudatus (pc) and processus pappillaris (pp), with two
determinations in each.
Figure 3. Stability study of clenbuterol in incurred urine (IU) stored at 4
°C, at -20 °C, at -60 °C and at successive freezing and thawing (f/t).
Figure 4. Stability study of clenbuterol in incurred liver (IL) stored at 4
°C, at -20 °C, at -60 °C and at successive freezing and thawing (f/t).
Table 1. Clenbuterol Concentration in Incurred Urine during Storage
storage
conditions n
av of clenbuterol
(ng mL-1) CV (%)
storage time
(weeks)
4 °C 17 5.32 6.26 12
-20 °C 26 4.97 9.63 20
-60 °C 24 5.06 8.62 20
6 f/t 26 5.04 9.27 20
Table 2. Clenbuterol Concentration in Incurred Liver during Storage
storage
conditions n
av of clenbuterol
(ng g-1) CV (%)
storage time
(weeks)
4 °C 22 19.13 8.30 20
-20 °C 28 18.68 7.56 20
-60 °C 27 18.13 6.63 20
6 f/t 28 19.07a 15.10a 20
a Rejecting data obtained at 12 weeks, the average clenbuterol concentration
it will be of 18.33 ng/g with a coefficient of variation of 10.41%.
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secondary amines reactions (22, 23) or as a result of protein
aggregation or denaturation during the freeze and thaw
cycles (24, 25). Is well-known that solute concentrations could
vary significantly depending upon the type of freezing employed
as well as the process scale, and this hypothesis should be
considered in this case since the affected samples were those
subjected to several freezing and thawing processes and not
those subjected to a uniform temperature. Otherwise this
abnormality could be justified only by random errors during
analysis. Therefore it was not problematic for clenbuterol
detection, and if rejecting the data obtained at 12 weeks, the
average clenbuterol concentration will be of 18.33 ng g-1 with
a coefficient of variation of 10.41%, closer to the CVm.
Comparing the average of clenbuterol results obtained at all
study temperatures for each matrix it could be seen that no one
differed from data obtained at the -60 °C studies, considered
the best temperature for optimal results.
In addition, assuming a linear performance for clenbuterol
concentration during storage, the data (average clenbuterol
concentration obtained each day) from stability tests, at each
set of storage conditions, was analyzed performing regression
analyses. Results obtained for urine (Table 3) and for liver
(Table 4) demonstrate that there was no tendency for clenbuterol
degradation during storage, at any of the temperatures studied
and storage times tested, since the slope obtained in each case
does not deviate significantly from zero.
As it could be seen in these experiments, concerning
clenbuterol determination, laboratorial samples of bovine urine
or liver can be preserved at +4 °C during, at least, 12 weeks,
for urine, and 20 weeks, for liver, since clenbuterol remains
without significant losses. Also, those samples can be stored at
-20 °C or at -60 °C during at least 20 weeks, with no
differences between these temperatures, and can be subjected
to 6 freezings and thawings during that time since there was
not a predictable significant loss of clenbuterol.
These conclusions allow one to contradict the opinion of
Gigosos and co-workers (13), concerning urine, and amplified
in the present work, for liver, about the risk of storing
laboratorial samples of urine for clenbuterol residue control,
because of the instability of clenbuterol in such a matrix.
The conclusions obtained in the present work are fundamental
for official residue control in animal production since it validates
the procedures implemented for laboratorial sampling, transport,
storage and analysis. Bovine urine or liver samples collected
for clenbuterol residue control can be transported at +4 °C, at
least during 24-48 h, or under freezing temperatures, and it
could be possible to store samples for up to 5 months before
screening or contra-analysis. Also samples can be frozen or
thawed, at least 6 times, allowing defreezing during transporta-
tion without any consequence in final results, which is very
important in the Azorean conditions. Moreover for the Azores
the possibility of screening those samples in loco could be
comparatively advantageous for meat certification and trade.
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